


NEUROMetrix®

NeuroMetrix, Inc.
Investor Relations Department
1000 Winter St. Attn: Accounts Payable
Attn: Accounts Payable
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: NURO

Last Trade:	1.79
Trade Time:	3:55 PM ET Aug 18, 2017
Change:	-0.03  (-1.648%)
Day Range	1.72 - 1.90
52-Week Range	1.66 - 13.84
Volume	14,456

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most commo... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 15, 2017*
[NeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep](#)
- Aug 3, 2017*
[NeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Denshi in Japan](#)
- Jul 27, 2017*
[NeuroMetrix Announces Shipment of 100,000th Quell Device Since Launch in 2015](#)
- Jul 20, 2017*
[NeuroMetrix Reports Q2 2017 Financial Results](#)
- Jul 13, 2017*
[NeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 9, 2017*
[Annual Report \(10-K\)](#)
- Aug 7, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Jul 20, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 20, 2017*
[Quarterly Report \(10-Q\)](#)
- Oct 20, 2016*
[Quarterly Report \(10-Q\)](#)